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Androgen receptors (ARs) which are implicated in the pathogenesis of several malignancies can also be a possible
downstream eﬀector in laryngeal cancer. In the present study, 97 invasive squamous laryngeal carcinomas were studied by
immunohistochemistryforproteinexpressionofAR.Androgenreceptorswereexpressedin52.6%oftumorspecimens,suggesting
their implication in the pathogenesis of this tumor. Our study’s aim was to investigate the hypothetical scenario of an androgen
refractory laryngeal carcinoma where androgen receptors can be activated by nodal molecules in the course of an Epithelial-to-
mesenchymal transition (EMT) phenomenon. In line with this we correlated AR expression with the expression of ILK, p-Akt,
E-cadherin, β-catenin in our sample as well as with tumor grade and TNM stage. A reverse correlation between nuclear AR and
cytoplasmic ILK expression was evidenced, indicating an interaction of those molecules in laryngeal carcinoma. Finally in our
material, in those carcinomas that were expressing ARs, stronger nuclear expression of the receptor was characterized by poorer
cell diﬀerentiation and correlated with the acquisition of EMT features like E-cadherin loss and β-catenin translocation raising a
question whether activated ARs can drive an EMT procedure.
1.Introduction
Larynx constitutes a hormone-target organ. It is during
puberty when under the inﬂuence of androgens the larynx
of males undergoes anatomical modiﬁcations leading to the
deepening of voice [1]. While androgens exert this already
known developmental function on larynx, it is highly possi-
ble that hormones still possess a role in the pathogenesis
of carcinomas deriving from this organ, similarly to what
happens in other malignancies like prostate cancer [2].
Androgens are steroids functioning through nuclear re-
ceptors, which can act as ligand-dependent transcription
factors. Prior to ligand binding, the androgen receptors
(ARs) are held inactive in the cytoplasm through association
with heat shock proteins and are precluded from DNA
binding. Ligand binding releases the inhibitory heat shock
proteins,andthereceptorrapidlytranslocatestothenucleus,
whereitbindsDNAasahomodimeronandrogenresponsive
elements within the regulatory regions of target genes which
are implicated in the cell cycle and apoptosis [3].
Previous studies have documented the expression of ARs
in laryngeal carcinoma and investigated their role in laryn-
geal carcinoma’s pathogenesis [4–6]. However, controversial
results about the expression of the receptor [7, 8]a n d
failure of antiandrogen therapies designed to eliminate the
hormonal level of patients [9] leaded to the early abandon-
ment of eﬀorts for such therapeutical approaches. Besides,
epidemiological data concerning laryngeal carcinoma shows
a pick incidence of that tumor in an age when a normal
reduction of androgen levels in males has already occurred
[10, 11]. Thus, androgens do not seem to have a clear par-
ticipation in laryngeal cancer pathogenesis.
In the case of prostate cancer where androgens are
essential for the progression of malignant cells, androgen
deprivation is a crucial therapeutic approach [12]. However
in the course of prostate cancer development, there is a phase2 ISRN Oncology
whencastratedlevelsoftestosteronefailtoinhibitthegrowth
of malignant cells [13], even if they still require androgen
receptor activity for their growth.
The molecular basis of the formation of an androgen-
refractory cancer implicates mainly AR mutations, AR gene
ampliﬁcation, and expression of coactivators that enhances
the AR action [13–15]. It is also possible that ARs can be
activated by molecules of signaling transduction pathways
that are being activated in malignant cells; for example, it is
reported in prostate carcinoma that the molecular pathway
activated by Human Epidermal growth factor Receptor-
2 (HER2) triggers Src association with ARs [13–15]. In
addition, IL-6 phosphorylates factors like STAT-3, MAPK,
PI3K/Akt, and Oncostatin M that are found to induce AR
activity [13–15]. We hypothesize that a similar condition
could take place in the case of laryngeal carcinoma.
Recently we found that integrin-linked kinase (ILK) and
p-Akt are overexpressed in laryngeal carcinoma [16]. Both
molecules have already been documented to be involved in
several processes thought to be critical in carcinogenesis,
including cell adhesion, aberrant cell proliferation, evasion
from apoptosis, promotion of angiogenesis, and tumor cell
invasiveness [17, 18]. The nodal role of ILK and p-
Akt in the crosstalk of several molecular pathways, their
capability to activate proteins via phosphorylation, and the
common molecular characteristics that depend both on
these molecules and on androgen receptors prompted us
to evaluate their correlation with the expression of ARs in
laryngeal cancer.
Currently there is a vast investigation on the way
malignantcellsacquireametastaticpotentialviaanepithelial
to mesenchymal transition (EMT) [19]. Downregulation of
E-cadherin and activation of β-catenin in a Wnt pathway
manner, that occur in the course of EMT, represents key
molecular events in the development and progression of
several human malignancies [20], including laryngeal cancer
[21, 22]. It is already suggested in the case of prostate cancer
t h a tA R sa r ei n v o l v edi nE M Tp r oc e s s[ 23]. Additionally, ARs
and Wnt pathway are shown to interact at many levels [24–
26], but no similar studies concerning laryngeal carcinoma
are available.
In a series of 97 invasive human laryngeal squamous
cell carcinomas we studied by immunohistochemistry the
expression of androgen receptors and we correlated them
with the expression of ILK, p-Akt (Ser 473), E-cadherin,
and β-catenin. We additionally correlated our results with
clinicopathological parameters such as tumor grade and
stage.
2.MaterialsandMethods
2.1. Tissue Specimens. The study was performed in accord-
ance with the institutional ethical guidelines and has been
approved by the Committee on Research and Ethics and the
Scientiﬁc Committee of the University Hospital of Patras,
Greece. Formalin-ﬁxed, paraﬃn-embedded tissue samples
from 97 primary human invasive squamous laryngeal car-
cinomas were obtained from the Department of Pathology,
Agios Andreas General Hospital, Patras, Greece. Adjacent
nonneoplastic laryngeal tissue was used as control. Our
material was randomly selected and was consisted of 2
women and 95 men. Ages ranged from 40 to 86 years, with
an average age of 60 years. The WHO classiﬁcation [27]o f
tumours was used to determine the histological grade: 25/97
tumours (25.8%) were classiﬁed as Grade I, 40/97 (41.2%)
as Grade II, and 32/97 (33%) as Grade III. Thirty two out of
97 (33%) tumours were stage I, 26/97 (26.8%) stage II, 17/97
(17.5%) stage III, and 22/97 (22.7%) stage IV A according to
TNM staging.
2.2. Immunohistochemistry. Representative 4μmt i s s u es e c -
tions were dewaxed in xylene and rehydrated in graded
ethanols. Antigen retrieval was enhanced by microwaving
the slides in 0.01M citrate buﬀer (pH = 6). Endogenous
peroxidase activity was quenched by treatment with 1%
hydrogen peroxide for 25min, followed by incubation with
protein blocking solution. Sections were subsequently incu-
bated with anti-AR (DAKO, Hamburg, Germany, dilution
1:20), for one hour in room temperature and primary
rabbit anti-ILK (Santa Cruz Biotechnology, CA, USA, dilu-
tion 1:500), rabbit anti-p-Akt (Ser473) (Cell Signaling,
Beverly, MA, dilution 1:40), mouse anti-β-catenin (BD
Biosciences,CA, USA, dilution 1: 2000), and mouse anti-
E-cadherin (BD Biosciences, CA, USA, dilution 1:2000)
overnight at 4◦C. Bound primary antibody was detected
using the biotin-streptavidin-peroxidase method (Envision
Detection Kit, DAKO, Hamburg, Germany) and visualized
usingdiaminobenzidineasthechromogen.Slideswerecoun-
terstained with haematoxylin, dehydrated and mounted. For
negative controls, blocking solution was added instead of the
primary antibody.
2.3. Immunohistochemical Evaluation. All slides were as-
sessed by one pathologist (H.P.) and one investigator (A.G.)
independently and blinded to the case. Both intensity of
staining and percentage of positive cells were taken into
account and the following scoring system was used: 0: no
staining or weak staining in less than 10% of tumor cells,
1: weak staining in 10–40% of tumor cells or moderate
staining in <40% of tumor cells, 2: weak staining in >70% of
cells, moderate staining in 40–70% of tumor cells or strong
staining in 10–40% of tumor cells, and 3: moderate staining
in >70% or strong staining in more than 40% of tumor cells.
Cases with score 0 were considered negative and cases with
scores 1, 2, or 3 were considered positive.
2.4. Statistical Analysis. Statistical analysis was performed
with the SPSS for Windows, release 15.0 (SPSS Inc.,
Chicago, IL, USA). Correlations of protein expression levels
with clinicopathological parameters were analyzed with
the nonparametric Kruskal-Wallis or Mann-Whitney tests
for ordinal data and chi-square test for nominal data.
Correlations between expression of proteins (immunohisto-
chemical scores) were evaluated by the Spearman rank-order
correlation coeﬃcient. Parametric tests were performed with
correction for ties. The signiﬁcance level was deﬁned as P<
0.05.ISRN Oncology 3
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Figure 1: (a) Non-neoplastic laryngeal tissue without AR expression (×200). (b) Nuclear expression of AR in laryngeal carcinoma. (×400).
Table 1: Correlation of Androgen receptors expression with E-cadherin, β-catenin, p-Akt, and ILK expression in laryngeal carcinoma by the
Spearman rank-order correlation coeﬃcient.
Membranous
E-cadherin
Membranous
β-catenin
Cytoplasmic
β-catenin
Nucleus
β-catenin
Cytoplasmic
p-Akt
Nucleus
p-Akt
Cytoplasmic
ILK
Nuclear r =− .067 r = .065 r = .000 r = .113 r =− .099 r = .100 r =− .260
AR P = 0.515 P = 0.527 P = 0.999 P = 0.270 P = 0.332 P = 0.332 Pa = 0.010
aP<0.05 was considered statistically signiﬁcant.
3. Results
3.1. Androgen Receptors Are Overexpressed in Laryngeal Car-
cinomas. Immunohistochemical staining for ARs was per-
formed in 97 tumors and adjacent nonneoplastic laryngeal
tissue. Immunoreactivity for ARs in adjacent nonneoplastic
laryngeal tissue was absent. In contrast 51/97 (52.6%) of
l a r y n g e a lt u m o r sw e r ep o s i t i v ef o rA R s( Figure 1). AR
expression was conﬁned to the nucleus of cancer cells. In
43.3% of carcinomas nuclear expression of AR was weak,
while moderate to strong AR immunostaining was observed
in only 9.3% of cases.
We documented a reverse correlation of the expression
of ARs in the nucleus with the expression of ILK in the
cytoplasm (r =− 0.260, P = 0.010). There was no
statistically signiﬁcant correlation of AR expression with p-
Akt, β-catenin, E-cadherin (Table 1), or tumour grade and
TNM stage (Table 2).
4. Discussion
Androgen receptors have a known developmental role in
several human malignancies functioning as transcription
factors [3]. In the present study we conﬁrmed the expression
of ARs in laryngeal carcinoma, as it was already shown by
previous studies [4–6].
The existence of an androgen-refractory laryngeal car-
cinoma could be an interesting hypothesis. According to it
ARs may retain their transcription factor activity without
the hormone been adapted on them but via activation
by molecular pathways that are functioning during EMT.
Most of the molecular pathways which are activated during
the course of EMT phenomenon intersect to nodal factors
like ILK and p-Akt [16] and, among others, conclude to
abolishment of E-cadherin from the cell membrane and
translocationofβ-cateninfromthemembranetothenucleus
[28].
In the current study we did not ﬁnd any correlation
between androgen receptors and p-Akt although it is known
in case of prostate cancer that androgen receptors can be
activated by the signaling transduction molecular pathway of
p-Akt [29, 30], revealing involvement of diﬀerent molecular
pathways in other malignancies.
Additionally, in the current study we show a correlation
of low expression of AR in tumors with ILK cytoplasmic
overexpression (r =− 0.260, P = 0.01) which possibly
suggests an interaction of those molecules in laryngeal
cancer, yet not in line with the hypothesis of ARs being
activated by ILK. It seems that ILK could oppose the acti-
vation of ARs in laryngeal carcinoma and thus their tumor
proliferative function. Nevertheless, a tumor suppressive role
of ILK has been described in several tumors [17, 31]. We
hypothesize that ILK could have a direct association with
ARs in the cytoplasm precluding them from activation by
other molecular pathways. Such an interaction between ILK
and AR has never been described in the literature; however
a similar hypothesis has been suggested for another nuclear
receptor ERα [31].
In our material, androgen receptor expression did not
correlate with the expression of β-catenin. This ﬁnding was
rather unexpected since there are studies that have docu-
mented multilevel interactions of androgen receptors with4 ISRN Oncology
Table 2: Androgen receptors expression in laryngeal carcinoma.
There is correlation with clinicopathological parameters.
Nuclear Androgen Receptora
N 0
n (%)
1
n (%)
2
n (%)
3
n (%)
P
valueb
Carcinomas
total 97 46
(47.4)
42
(43.3)
6
(6.2)
3
(3.1)
Grade 0.852
I2 5 13
(52)
10
(40)
2
(8)
0
(0)
II 40 19
(47.5)
16
(40)
4
(10)
1
(2.5)
III 32 14
(43.8)
16
(50)
0
(0)
2
(6.2)
TNM Stage 0.890
I3 2 13
(40.6)
17
(53.2)
1
(3.1)
1
(3.1)
II 26 14
(53.8)
8
(30.8)
2
(7.7)
2
(7.7)
III 17 9
(53)
7
(41.1)
1
(5.9)
0
(0)
IV 22 10
(45.5)
10
(45.5)
2
(9)
0
(0)
aAR expression was scored as described in methods. bKruskal-Wallis or
Mann-Whitney test; P<0.05 was considered statistically signiﬁcant.
Wnt pathway components in other types of carcinomas.
Firstly AR can act as cofactors of the β-catenin/LEF tran-
scription factor [24, 25]. Additionally, androgen receptors
are transcription targets of β-catenin/LEF transcription
factor [24]. Finally, ARs can potentially be activated either
by β-catenin being adapted on them [21] or by GSK-3b
phosphorylation [24]. Nevertheless, it is commendable that
when we excluded the cases that had negative AR expression
we documented a statistically signiﬁcant correlation between
the intensity of AR expression, the abolishment of β-catenin
from the membrane (r =− 0.762, P = 0.017), and its
translocation to the nucleus (r = 0.791, P = 0.011). In those
selected cases we also show a correlation between intense
nuclear expression of AR and abolishment of E-cadherin
from the membrane (r =− 0.671, P = 0.048).
In our total sample we failed to correlate AR expression
with clinicopathological parameters; yet, in the selected cases
characterized by any detection of AR nuclear expression, we
documentedacorrelationofintenseARexpressionwithhigh
Grade tumors (r = 0.707, P = 0.033).
In conclusion, taking into account the limitations of our
study, such as small sample size, descriptive character and
lack of genomic, and transcriptional and posttranscriptional
analysis, we evidenced androgen receptor expression in
laryngeal cancer suggesting a possible role in the pathogene-
sis of that malignancy. We investigated the hypothetical sce-
nario of an androgen refractory laryngeal carcinoma where
androgen receptors can be activated by nodal molecules in
the course of EMT. We suggest that ILK among others could
possibly exert a role in such a molecular crosstalk; however
further research is needed to support that consumption. Fi-
nally in our material interestingly in those carcinomas that
were expressing ARs, stronger nuclear expression of the
receptor was characterized by poorer cell diﬀerentiation and
correlated with the acquisition of EMT features like E-
cadherin loss and β-catenin translocation raising a question
whether activated ARs can contribute together with other
molecular pathways to the development of an Epithelial-
Mesenchymal Transition in the course of laryngeal carci-
noma metastasis. Further investigation is needed to evaluate
AR and the molecular pathways of cancer that can activate
it, as potential molecular targets for laryngeal carcinoma
therapy.
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